Brief: Unicycive Completes Enrollment For An Investigational Treatment Of Hyperphosphatemia In Dialysis Patients

Unicycive Therapeutics

10/11/2022 13:30

Nov 10 (Reuters) - Unicycive Therapeutics Inc  UNCY.O :
    * UNICYCIVE COMPLETES ENROLLMENT OF PIVOTAL BIOEQUIVALENCE
STUDY
FOR RENAZORB™ (LANTHANUM DIOXYCARBONATE), AN INVESTIGATIONAL
TREATMENT FOR HYPERPHOSPHATEMIA IN CHRONIC KIDNEY DISEASE (CKD)
PATIENTS ON DIALYSIS
    * UNICYCIVE THERAPEUTICS INC - TOPLINE DATA EXPECTED BY YEAR
END
2022
    * UNICYCIVE THERAPEUTICS INC - ON TRACK TO FILE NDA IN 2023

Source text for Eikon:  ID:nGNXMt2Jg 
Further company coverage:  UNCY.O 
 ((Reuters.Briefs@thomsonreuters.com;))